Acne News and Research

Latest Acne News and Research

NovaBay Pharmaceuticals reports net income of $2.7M for 2009 against year-ago loss

NovaBay Pharmaceuticals, Inc., a clinical stage specialty pharmaceutical company developing first-in-class, anti-infective compounds for the treatment and prevention of antibiotic-resistant infections, today reported full-year and fourth quarter financial results for 2009. The company also highlighted recent progress of its proprietary and partnered development programs.

30 Mar 2010

Erbitux can now be used in Japan as 1st-line treatment for mCRC: Merck Serono

Merck Serono, a division of Merck KGaA, Darmstadt, Germany, announced today that Erbitux® (cetuximab) can now be used in Japan in combination with chemotherapy in the 1st-line treatment for patients with epidermal growth factor receptor -expressing, curatively unresectable (inoperable), advanced or recurrent colorectal cancer carrying the KRAS wildtype gene.

29 Mar 2010

Health Canada accepts Cipher Pharmaceuticals' NDS for CIP-TRAMADOL ER

Cipher Pharmaceuticals Inc. today announced that its New Drug Submission (NDS) to Health Canada for CIP-TRAMADOL ER, its extended-release formulation of tramadol, has been accepted for review. The Company expects the review to be completed by early 2011.

26 Mar 2010

Helix BioMedix reports revenue of approximately $391,000 in 2009

Helix BioMedix, Inc., a developer of bioactive peptides, announced financial results for the year ended December 31, 2009.

26 Mar 2010

Skinvisible obtains Korean patent for polymer delivery system

Skinvisible, Inc. announced today that the South Korean patent office has granted a patent for Invisicare®, the company's polymer delivery system for topical dermatology products.

24 Mar 2010

China Sky One Medical prepares for commercial launch 13 new SFDA approved products

China Sky One Medical, Inc., a leading fully integrated pharmaceutical company producing over-the-counter drugs in the People's Republic of China, today announced the pending commercial launch of 13 new SFDA approved products over the next few quarters.

22 Mar 2010

Galderma Laboratories' Differin Lotion receives FDA approval

Galderma Laboratories, L.P. today announced the U.S. Food and Drug Administration approval of Differin® (adapalene) Lotion, 0.1%, the first-ever lotion formulation of the well-tolerated retinoid adapalene, for the treatment of acne. Differin Lotion, 0.1% will be available by prescription in April 2010.

22 Mar 2010

Effective defense against HIV: Acne drug minocycline

Johns Hopkins scientists have found that a safe and inexpensive antibiotic in use since the 1970s for treating acne effectively targets infected immune cells in which HIV, the virus that causes AIDS, lies dormant and prevents them from reactivating and replicating.

20 Mar 2010

Acne drug prevents HIV breakout

18 Mar 2010

Pimple Clinic program donates acne products to low-income families

The Pimple Clinic, a safe, effective non-prescription line of acne products developed by the dermatologist who founded Skinstore.com, is being provided to low-income teens that otherwise cannot afford acne treatments.

17 Mar 2010

Helix BioMedix enters into distribution agreement with RubyDerm Bio

Helix BioMedix, Inc., a developer of bioactive peptides, announced that the Company entered into an agreement with RubyDerm Bio, Inc. under which RubyDerm will assume responsibility, on an exclusive basis, for the distribution of certain of Helix BioMedix’s branded prestige skin care products to spas, beauty stores, hospitals, clinics, physicians, and consumers in South Korea, China and Japan.

11 Mar 2010

Safeguard Scientifics' aggregate partner company revenue rises 46% in 2009

Safeguard Scientifics, Inc., a holding company that builds value in growth-stage life sciences and technology companies, today announced that aggregate revenue of its partner companies for the year was $262 million, up 46% from $179 million in 2008, exceeding the company’s 2009 guidance of $223 million to $243 million, as adjusted to reflect the inclusion of two new partner companies.

11 Mar 2010

Helix BioMedix announces additional funding of $2.9M through convertible promissory notes

Helix BioMedix, Inc., a developer of bioactive peptides, announced additional funding in the amount of $2.9 million through convertible promissory notes. The company also announced the addition of Lawrence Blake Jones to its board of directors.

10 Mar 2010

DUSA Pharmaceuticals to unveil BLU-U Blue Light Photodynamic Therapy Illuminator at AAD meeting

DUSA Pharmaceuticals, Inc.®, a specialty pharmaceutical company focused on dermatology, will unveil an ergonomically enhanced BLU-U® Blue Light Photodynamic Therapy Illuminator at this year's American Academy of Dermatology meeting in Miami, Florida, March 5-9. BLU-U, in conjunction with the Levulan® Kerastick® topical treatment, is an integral part of the Levulan® Photodynamic Therapy (PDT) technology platform.

5 Mar 2010

People with skin of color more prone to dermatologic problems than those with lighter skin tones

According to projections from the United States Census Bureau, people with skin of color will comprise approximately half of the U.S. population by 2050. This group, which includes African-Americans, Asians, Latinos and other ethnicities, are more prone to certain dermatologic problems than those with lighter skin tones due to their genetic make-up and in some cases cultural practices.

5 Mar 2010

Proper diagnosis, treatment and good skin care help control acne and rosacea

Acne and rosacea are two seemingly different skin conditions that have one important thing in common: both are chronic and extremely common skin conditions. However, dermatologists recommend that with proper diagnosis, treatment and a healthy dose of good, old-fashioned skin care, acne and rosacea can be less of a nuisance for patients.

5 Mar 2010

Dermatologist speaks about common forms of hair loss and treatment options at 68th Annual Meeting

For many women, unexplained hair loss can take a significant psychological toll on their overall quality of life. From altering their hairstyle to hide a thinning part to scaling back their hair care regimen in an effort to halt further hair loss, women try countless ways to cover up this problem - and the results are often lukewarm at best.

4 Mar 2010

Top ten beauty treatments

RoxSpa, one of the most prestigious and luxurious medi-spas in Beverly Hills, announces their annual 'Top Ten' face and body rejuvenation treatments that are both highly-effective and provide the most satisfying results.

4 Mar 2010

Solta Medical acquires Aesthera

Solta Medical, Inc., a global leader in the medical aesthetics market, today announced the successful completion of its acquisition of Aesthera Corporation.

1 Mar 2010

Solta Medical announces definitive agreement to acquire Aesthera

Solta Medical, Inc., a global leader in the medical aesthetics market, today announced it has entered into a definitive agreement to acquire privately-held Aesthera Corporation, which is based in Pleasanton, California. Under the terms of the definitive agreement, Solta will acquire Aesthera for $5.25 million in Solta common stock and cash, with potential additional base line milestones of $750,000 for a consideration of $6.0 million. Excluding acquisition and integration related charges, the transaction is expected to be accretive to Solta Medical's earnings within twelve months.

23 Feb 2010